As the Australian share market prepares for a mixed opening, with influences from Wall Street's recent gains and concerns over rising bond yields, investors are keenly observing sectors that may offer growth potential. In such an environment, stocks with high insider ownership can be particularly appealing, as they often indicate confidence in the company's future prospects by those who know it best.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Wisr (ASX:WZR) | 15.7% | 94.2% |
| Torque Metals (ASX:TOR) | 19.7% | 70.8% |
| Starpharma Holdings (ASX:SPL) | 17.3% | 75.1% |
| SKS Technologies Group (ASX:SKS) | 14.7% | 28.3% |
| Lunnon Metals (ASX:LM8) | 10.9% | 39.7% |
| Forrestania Resources (ASX:FRS) | 24.8% | 72.9% |
| Barton Gold Holdings (ASX:BGD) | 19.7% | 86.7% |
| Austral Resources Australia (ASX:AR1) | 24% | 28.2% |
| Adveritas (ASX:AV1) | 17.6% | 99.9% |
| Advanced Engineered Materials (ASX:AEM) | 35.1% | 58.7% |
We're going to check out a few of the best picks from our screener tool.
Cogstate (ASX:CGS)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Cogstate Limited is a neuroscience solutions company that focuses on the creation, validation, and commercialization of digital brain health assessments globally, with a market cap of A$648.40 million.
Operations: The company generates revenue from two main segments: Healthcare (including Sport) at $2.50 million and Clinical Trials (including the Precision Recruitment Tool & Research) at $58.37 million.
Insider Ownership: 28.2%
Cogstate demonstrates strong growth potential with a forecasted annual earnings increase of 22.44%, surpassing the Australian market average. The company's revenue is expected to grow at 15.6% annually, outpacing the broader market's 5%. Recent financial results show increased sales and net income, while substantial insider ownership aligns management interests with shareholders. Despite trading below estimated fair value, Cogstate maintains high-quality earnings and robust future revenue visibility of $118.5 million (A$).
- Delve into the full analysis future growth report here for a deeper understanding of Cogstate.
- According our valuation report, there's an indication that Cogstate's share price might be on the cheaper side.
Clarity Pharmaceuticals (ASX:CU6)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on the research and development of radiopharmaceutical products for oncology in Australia and the United States, with a market cap of A$671.55 million.
Operations: The company generates revenue primarily through its radiopharmaceutical development segment, which accounted for A$10.53 million.
Insider Ownership: 13.2%
Clarity Pharmaceuticals is positioned for growth, trading 65.6% below its estimated fair value and forecasted to achieve high earnings growth of 53.87% annually. The company is expected to become profitable in the next three years, with a return on equity projected at 42.6%. Recent clinical trial advancements in prostate cancer treatment underscore Clarity's innovative potential, while insider ownership ensures alignment with shareholder interests despite current revenue challenges and substantial net losses reported recently (A$107.24 million).
- Dive into the specifics of Clarity Pharmaceuticals here with our thorough growth forecast report.
- Upon reviewing our latest valuation report, Clarity Pharmaceuticals' share price might be too pessimistic.
Energy One (ASX:EOL)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Energy One Limited provides software products, outsourced operations, and advisory services to wholesale energy, environmental, and carbon trading markets in Australasia and Europe, with a market cap of A$479.70 million.
Operations: The company generates revenue from the Energy Software Industry segment, amounting to A$69.56 million.
Insider Ownership: 26%
Energy One is trading at 64.3% below its fair value, with earnings projected to grow significantly at 30.77% annually, outpacing the Australian market's growth rate. Recent financial results show an increase in net income to A$8.13 million from A$5.89 million last year. The company was added to the S&P Global BMI Index and is subject to a proposed acquisition by Volue AS for A$565 million, pending regulatory approvals and due diligence completion.
- Unlock comprehensive insights into our analysis of Energy One stock in this growth report.
- Our comprehensive valuation report raises the possibility that Energy One is priced lower than what may be justified by its financials.
Next Steps
- Reveal the 116 hidden gems among our Fast Growing ASX Companies With High Insider Ownership screener with a single click here.
- Ready To Venture Into Other Investment Styles? The end of cancer? These 35 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com